Skip to main content

Table 3 Overall treatment duration in the Safety population (N = 32)

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

  Months of treatment  
  < 4 4 > 4 Total
No. of patients 3 14 15 32
Median duration (range) (in days) 65 (56–94) 121 (105–130) 214 (138–258) 129.5 (56–258)
Mean duration ± SD (in days) 71.7 ± 19.9 120.1 ± 7.1 200.9 ± 46.4 153.5 ± 57.1